Zeria Plans 2009 Test Of Compound For Easing Cancer Pain
This article was originally published in PharmAsia News
Executive Summary
Japan's Zeria Pharmaceutical says it expects to begin Phase II trials in Europe next year to test its pancreatic cancer compound, Z-360. The drug was developed to treat stomach ulcers, but Zeria redeveloped it to treat gastrointestinal cancers. Z-360 failed in previous trials to shrink tumors, but researchers noted it helped to ease patient pain. In next year's trials, Zeria plans to test the gastrin CCK2 receptor antagonist in combination with Eli Lilly's Gemzar (gemcitabine). (Click here for more - a subscription may be required